More articles from In vitro and In vivo Oncology

You have access
Attempts to improve the pharmacokinetic Profile of Pharmacophore-modified 99mTc-N4-conjugated GRPR-targeted Compounds via Addition of a Ga-DOTA moiety
Thomas Guenther, Sebastian Fischer, Angela Casini, Constantin Lapa and Wester Hans-Juergen

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4057;
You have access
A human antibody against TIP1 targets lung cancer in vitro and patient-derived xenografts in vivo.
Abhay Singh, Calvin Lewis, Cristian Wieczorek Villas Boas, Prashant Jethva, Buck Rogers, Dennis Hallahan and Vaishali Kapoor

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4061;
You have access
Advantages of FBPA PET in evaluating early response of anti PD-1 immunotherapy in tumor-bearing mice: comparison to FDG PET
Mitsuaki Tatsumi, Fumihiko Soeda, Tadashi Watabe, Sadahiro Naka, Kazuhiro Ooe, Kenta Kurimoto, Daisuke Katayama and Hiroki Kato

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4016;
You have access
Evaluation of Radionuclide Stimulated Therapy response in a preclinical multiple myeloma model
ANCHAL GHAI, Alexander Zheleznyak, Christopher Egbulefu, Kvar Black, Rui Tang, Mathew Cooper, Ravi Vij, Monica Shokeen, John DiPersio and Samuel Achilefu

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4063;
You have access
Fibroblast Activation Protein (FAP) as a Target for Radioligand Therapy in Glioblastoma
Pauline Jeanjean, Samantha Kwock, Christopher Tse, Timothy Cloughesy, Johannes Czernin, Giuseppe Carlucci, David Nathanson, Christine Mona and Elie Besserer-Offroy

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4050;
You have access
A preclinical study of minibody 177Lu-DOTA-IAB2 targeting PSMA for Radiopharmaceutical Therapy of Prostate Cancer
Fang Jia, Gareth Smith, Leticia Maria De Souza Cordeiro, Kelley Diaz, Ian Wilson and Alessandro Mascioni

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4027;
You have access
Development of 177Lu-labeled antibody-drug conjugate for improving treatment efficacy of radioimmunotherapy for solid tumors
Aiko Yamaguchi, Wei Xiong, Chisato Yamazaki, Yasuaki Anami, Ningyan Zhang, Zhiqiang An and Kyoji Tsuchikama

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4065;
You have access
Preliminary evaluation of 131I-labeled ITGA5 inhibitor for targeted radionuclide therapy of pancreatic cancer xenografts
Tao Wang

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4021;
You have access
Immuno-PET using 89Zr-labeled Glypican-1 antibody: a novel theranostic probe for the antibody-drug conjugate treatment in pancreatic cancer
Tadashi Watabe, Sadahiro Naka, Satoshi Serada, Eku Shimosegawa and Tetsuji Naka

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4041;
You have access
The journey to a novel theranostic for prostate cancer : the preclinical study of 64Cu-DOTHA2-PSMA
Marie-Christine Milot, Ophelie Belissant Benesty, Veronique Dumulon-Perreault, Samia Ait-Mohand, Sameh Geha, Patrick Richard, Etienne Rousseau and Brigitte Guerin

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4025;

Main menu

User menu

Search

More articles from In vitro and In vivo Oncology

Pages